To counter unmet market needs and provide better treatment choices for WHIM Syndrome, several market players are working robustly either on single-agent novel molecules or on combination and dose modification of standard therapies. Several therapies are expected to be launched in the study period, likely to drive market growth during the study period.
DelveInsight’s “WHIM Syndrome Market Insights, Epidemiology, and Market Forecast 2032″ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the WHIM Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The WHIM Syndrome market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
WHIM Syndrome: An Overview
WHIM syndrome is a primary immunodeficiency disorder, one of a group of disorders characterized by irregularities in the cell development and/or cell maturation process of the immune system. The term WHIM is an acronym for the main signs of the syndrome: warts, hypogammaglobulinemia, infections, and myelokathexis. It is an autosomal-dominant combined immunodeficiency disease caused by mutations in the receptor CXCR4, resulting in increased bone marrow retention and severe reduction in circulating neutrophils.
WHIM Syndrome Market Key Facts
-
The total number of diagnosed prevalent cases of WHIM Syndrome associated in 7MM countries was approximately 180 in 2021.
-
Among EU5 countries, Germany had the highest number of prevalent cases of WHIM Syndrome (Around 20 cases) in 2021.
-
Japan had about 30 prevalent cases of WHIM Syndrome in 2021.
-
The 2021 annual report of the French Chronic Neutropenia Registry reported that the number of WHIM patients in France was 15 (Registre Français des neutropénies Chroniques & sévères, 2021).
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted WHIM Syndrome market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the WHIM Syndrome market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
WHIM Syndrome Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the WHIM Syndrome Epidemiology, Segmented as –
-
Total Diagnosed Prevalent Cases of WHIM Syndrome [2019–2032]
-
Gender-specific Cases of WHIM Syndrome [2019–2032]
-
Age-specific Cases of WHIM Syndrome [2019–2032]
WHIM Syndrome Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the WHIM Syndrome market or expected to be launched during the study period. The analysis covers the WHIM Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the WHIM Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the WHIM Syndrome Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/whim-syndrome-market
Latest Key Update in the WHIM Syndrome Therapeutics Market
On April 12, 2023, X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) announced that its submitted late-breaker abstract entitled “Results of a Phase 3 Trial of an Oral CXCR4 Antagonist, Mavorixafor, for Treatment of Patients With WHIM Syndrome” has been accepted for oral presentation at the Annual Meeting of the Clinical Immunology Society (CIS), which is taking place May 18-21, 2023, in St. Louis, MO. New data related to clinical secondary endpoints, among other assessments, are to be presented.
WHIM Syndrome Therapeutics Analysis
The treatment for WHIM syndrome can be mainly categorized into two categories: curative treatment and symptomatic treatment. Hematopoietic stem cell transplantation (allogenic) is the only available curative treatment for WHIM syndrome, whereas the symptomatic treatment involves the exogenous administration of immunoglobulins (IV/subcutaneous), G-CSF, and CXCR4 antagonists.
Several major pharma and biotech companies are developing therapies for WHIM Syndrome to further improve the treatment scenario. Currently, X4 Pharmaceuticals is leading the therapeutics market with its WHIM Syndrome drug candidates in the mid to advanced stage of clinical development.
The Leading Players in the WHIM Syndrome Therapeutics Market Include:
-
National Institute of Allergy and Infectious Diseases (NIAID)
-
Amgen
-
Sandoz (Novartis)
-
Pfizer
-
Takeda
-
X4 Pharmaceuticals
And Many Others
WHIM Syndrome Emerging and Marketed Drugs Covered in the Report Include:
-
Mavorixafor (X4P-001): X4 Pharmaceuticals
-
Plerixafor (Mozobil, AMD3100): National Institute of Allergy and Infectious Diseases (NIAID)
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/whim-syndrome-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. WHIM Syndrome Competitive Intelligence Analysis
4. WHIM Syndrome Market Overview at a Glance
5. WHIM Syndrome Disease Background and Overview
6. WHIM Syndrome Patient Journey
7. WHIM Syndrome Epidemiology and Patient Population (In the US, EU5, and Japan)
8. WHIM Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. WHIM Syndrome Unmet Needs
10. Key Endpoints of WHIM Syndrome Treatment
11. WHIM Syndrome Marketed Products
12. WHIM Syndrome Emerging Drugs and Latest Therapeutic Advances
13. WHIM Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. WHIM Syndrome Market Outlook (In US, EU5, and Japan)
16. WHIM Syndrome Access and Reimbursement Overview
17. KOL Views on the WHIM Syndrome Market
18. WHIM Syndrome Market Drivers
19. WHIM Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/whim-syndrome-marke
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Solutions
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/